Takeda Clinical Trial Pipeline — 202 Active Studies

Phase 1: 12, Phase 2: 39, Phase 3: 59, Other: 92

Takeda's pipeline spans oncology, gastroenterology, rare disease, and plasma-derived therapies. Their oncology franchise includes Alunbrig (brigatinib) for ALK-positive NSCLC — competitive with Lorbrena in the post-crizotinib setting — and Ninlaro (ixazomib), the first oral proteasome inhibitor for multiple myeloma. In gastroenterology, Entyvio (vedolizumab) for IBD has one of the most active label expansion programs in the specialty. Their rare disease portfolio (alpha-1 antitrypsin deficiency, Fabry disease, hereditary angioedema) continues generating Phase 3 trials. Takeda is also advancing TAK-279 (zasocitinib), a TYK2 inhibitor, as a potential competitor to Bristol Myers Squibb's deucravacitinib in psoriasis and PsA.

• Oncology (NSCLC, multiple myeloma, lymphoma)
• Gastroenterology / IBD
• Rare / plasma-derived
• Neuroscience
• Immunology (TYK2, IL)

• Alunbrig (brigatinib) — ALK inhibitor, NSCLC
• Ninlaro (ixazomib) — oral proteasome inhibitor, myeloma
• Entyvio (vedolizumab) — α4β7 integrin, IBD/Crohn's/UC
• TAK-279 (zasocitinib) — TYK2 inhibitor, psoriasis/PsA
• Fruquintinib — VEGFR 1/2/3 inhibitor, CRC (via Zymeworks)
• TAK-981 — SUMO pathway inhibitor, lymphoma

Takeda's TYK2 inhibitor zasocitinib is the most significant competitive threat to BMS's deucravacitinib (Sotyktu) in the psoriasis/PsA space. Any dermatology-focused company should monitor Takeda's Phase 3 program. In GI, new Entyvio combinations and IBD programs are closely watched by companies developing competing gut-selective biologics.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Takeda's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Takeda may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.